Icotrokinra results demonstrate skin clearance in patients with difficult-to-treat scalp and genital psoriasis

Johnson & Johnson have recently announced their new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra, the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. The study evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least moderate plaque psoriasis affecting high-impact skin sites.

Icotrokinra demonstrated high rates of skin clearance in patients with scalp psoriasis as 66% achieved a scalp-specific Investigator’s Global Assessment score of 0/1 compared to 11% receiving placebo at Week 16. At the same time point, among patients with genital psoriasis, 77% treated with icotrokinra achieved a static Physician’s Global Assessment of Genitalia score of 0/1 compared to 21% receiving placebo. In the smaller subset of patients with hand/foot psoriasis, treatment with icotrokinra showed a numerically higher rate of skin clearance at Week 16 with 42% achieving a hand and/or foot Physician’s Global Assessment score of 0/1 compared to 26% receiving placebo.

“While plaque psoriasis can appear in any location on the body, most high-impact skin sites affect areas critical for mobility, personal care, and intimacy, and can be very challenging to treat effectively. Notably, almost 80% of psoriasis patients experience scalp involvement,” said Melinda Gooderham, MSc, MD, FRCPC, SKiN Centre for Dermatology, Queen’s University, and Probity Medical Research, Peterborough, ON, Canada and ICONIC-TOTAL study investigator.^f “Results from the ICONIC-TOTAL study demonstrate impressive rates of skin clearance in these difficult-to-treat areas and show the potential for treatment with icotrokinra to offer patients a novel therapeutic option that aligns with their treatment needs and preferences.”

---

---

Related Topics and Keywords

genital psoriasis, Icotrokinra, johnson and johnosn